UB Paderborn / Katalog / Suche / in CDI

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

BMC cancer, 2022-11, Vol.22 (1), p.1219-11, Article 1219

2022

Volltextzugriff (PDF)

BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases

British journal of surgery, 2019-08, Vol.106 (9), p.1237-1247

2019

Volltextzugriff (PDF)

Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma

Digestive and liver disease, 2020-06, Vol.52 (6), p.658-667

2020

Volltextzugriff (PDF)

P318 Performance of rectosigmoidoscopy and rectoscopy to assess endoscopic and histological healing in ulcerative colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i702-i702

2024

Volltextzugriff (PDF)

Gastrointestinal: Disseminated Kaposi's sarcoma

Journal of gastroenterology and hepatology, 2018-07, Vol.33 (7), p.1309-1309

2018

Volltextzugriff (PDF)

Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study

Annals of oncology, 2019-07, Vol.30, p.iv99-iv100

2019

Volltextzugriff (PDF)

Characteristics, survival rates and therapeutic efficacy in vipomas : a national multicentric retrospective study of the GTE

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2020-11, Vol.20, p.S3-S4

2020

Volltextzugriff (PDF)

Mise au point sur les tumeurs stromales gastro-intestinales (GIST)

Oncologie (Paris, France), 2018-10, Vol.20 (5-6), p.117-127

2018

Volltextzugriff (PDF)

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study

ESMO open, 2023-06, Vol.8 (3), p.101574-101574, Article 101574

2023

Volltextzugriff (PDF)

Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii186

2018

Volltextzugriff (PDF)

2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S430-S430

2015

Volltextzugriff (PDF)

1365 CYTOKERATIN 18 IN SEVERE ACUTE ALCOHOLIC HEPATITIS

Journal of hepatology, 2012-04, Vol.56, p.S536-S536

2012

Volltextzugriff (PDF)

1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)

Annals of oncology, 2021-09, Vol.32, p.S1095-S1095

2021

Volltextzugriff (PDF)

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Journal of clinical oncology, 2022-01, Vol.40 (3), p.262-271

2022

Volltextzugriff (PDF)

629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)

Annals of oncology, 2023-10, Vol.34, p.S448-S448

2023

Volltextzugriff (PDF)

A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

Annals of oncology, 2019-10, Vol.30, p.v318-v319

2019

Volltextzugriff (PDF)

830TiP - A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

Annals of oncology, 2019-10, Vol.30, p.v318-v319

2019

Volltextzugriff (PDF)

120P Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort

Annals of oncology, 2023-10, Vol.34, p.S227-S227

2023

Volltextzugriff (PDF)

387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study

Annals of oncology, 2022-09, Vol.33, p.S713-S714

2022

Volltextzugriff (PDF)

P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease

Journal of Crohn's and colitis, 2023-02, Vol.17 (Supplement_1), p.i475-i476

2023

Volltextzugriff (PDF)

429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

Annals of oncology, 2021-09, Vol.32, p.S548-S549

2021

Volltextzugriff (PDF)

119P Management of biliary tract cancers in older patients: A French multicenter cohort study

Annals of oncology, 2023-10, Vol.34, p.S226-S227

2023

Volltextzugriff (PDF)

608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort

Annals of oncology, 2023-10, Vol.34, p.S437-S437

2023

Volltextzugriff (PDF)

522TiP PRODIGE 71 - BEVAMAINT: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer

Annals of oncology, 2020-09, Vol.31, p.S460-S460

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases

Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma

P318 Performance of rectosigmoidoscopy and rectoscopy to assess endoscopic and histological healing in ulcerative colitis

Gastrointestinal: Disseminated Kaposi's sarcoma

Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study

Characteristics, survival rates and therapeutic efficacy in vipomas : a national multicentric retrospective study of the GTE

Mise au point sur les tumeurs stromales gastro-intestinales (GIST)

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study

Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort

2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma

1365 CYTOKERATIN 18 IN SEVERE ACUTE ALCOHOLIC HEPATITIS

1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)

A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

830TiP - A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

120P Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort

387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study

P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

119P Management of biliary tract cancers in older patients: A French multicenter cohort study

608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort

522TiP PRODIGE 71 - BEVAMAINT: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer

Suchergebnisse filtern